Nippon Chemical Industrial Co.,Ltd. FY2027 Q1 Earnings Report

Quick View

Executive Summary

The most important point for FY2027 Q1 is that the trend of revenue and profit growth continued, while net income declined due to the reversal of the prior-year extraordinary gain. Revenue increased to ¥110.4B (+0.8% YoY), Operating Income to ¥11.7B (+5.0%), and Ordinary Income to ¥12.3B (+8.7%), while Net Income fell significantly to ¥9.0B (-24.9%). The decline in Net Income was attributable to the reversal of the ¥5.1B gain on the sale of fixed assets recorded in the same period of the previous year. Underlying earnings power remained solid, supported by an improved gross margin and control of SG&A expenses.

Factors Affecting Performance

【Revenue】Revenue was ¥110.4B, essentially flat at +0.8% YoY. The Chemicals Business expanded to ¥50.0B (+4.4%), while the Functional Products Business declined slightly to ¥57.4B (-2.2%), with the two businesses offsetting each other. The Leasing Business remained stable at ¥2.4B (+0.4%), despite its small scale.

【Profit and Loss】Gross profit was ¥25.7B, and the gross margin improved to 23.3% from the previous year. After absorbing SG&A expenses of ¥14.0B (SG&A ratio: 12.7%), the Company recorded Operating Income of ¥11.7B (+5.0%) and an operating margin of 10.6%. By segment, the Functional Products Business made the largest contribution, with Operating Income of ¥6.2B (+7.5%, margin: 10.8%), followed by the Chemicals Business at ¥4.0B (+2.6%, margin: 8.0%) and the Leasing Business at ¥1.5B (+9.4%, margin: 64.7%). Ordinary Income increased to ¥12.3B (+8.7%), supported by an improvement in non-operating income and expenses, including interest and dividend income of ¥0.8B and equity-method income of ¥0.3B. Meanwhile, Net Income was ¥9.0B (-24.9%) due to the reversal of the ¥5.1B gain on the sale of fixed assets recorded in the previous year. Extraordinary items consisted only of a ¥0.02B loss in the current period, indicating that temporary factors were limited. Overall, the Company achieved revenue and operating profit growth, while the decline in Net Income was an apparent decrease caused by the reversal of an extraordinary factor.

Segment Analysis

The Functional Products Business was the largest segment by revenue mix (¥57.4B, 52.0% of total Company revenue), and also made the largest contribution to profit, accounting for ¥6.2B of Operating Income (53.2% of total Company Operating Income). The Chemicals Business remained resilient, with revenue of ¥50.0B (45.3% of the composition), Operating Income of ¥4.0B, and a margin of 8.0%. The Leasing Business was small, with revenue of ¥2.4B, but had an exceptionally high margin of 64.7%, contributing to the stability of overall Company earnings. The margin differential between the Functional Products Business and the Chemicals Business (10.8% versus 8.0%) illustrates the impact of changes in the business mix on the Company-wide operating margin. Maintaining the proportion of the Functional Products Business will be key to future margin trends.

Key Financial Indicators

【Profitability】The operating margin improved to 10.6% from the previous year, with the balance between the 23.3% gross margin and 12.7% SG&A ratio contributing to margin expansion. The net margin was 8.2%, but the underlying earnings profile remained stable after excluding the reversal of the prior-year extraordinary gain.【Cash Flow Quality】Accounts receivable of ¥118.9B and inventories of ¥42.4B are high relative to the scale of revenue, indicating room for improvement in collection and inventory efficiency.【Investment Efficiency】ROE was 1.6%, while total asset turnover remained low. A substantial increase in investment securities (¥128.8B, +151.4% YoY) increased total assets and suppressed the turnover ratio.【Financial Soundness】The Equity Ratio was 65.1%, indicating a conservative and stable financial base.

Cash Flow Analysis

Although detailed disclosure of the Operating Cash Flow statement is unavailable, balance sheet trends indicate that working capital is becoming increasingly tied up. Accounts receivable of ¥118.9B and inventories of ¥42.4B remained high relative to the scale of revenue, and this capital lock-up may be creating a time lag in the generation of operating cash. Meanwhile, accounts payable increased to ¥44.2B (+36.8% YoY), suggesting expanded purchasing activity or changes in payment terms. Investment securities accumulated substantially to ¥128.8B, indicating progress in capital allocation toward investment activities. Construction in progress of ¥39.3B suggests that capital expenditures are continuing. Consequently, the balance between investment and working capital management will influence future Free Cash Flow trends.

Earnings Quality

The current period’s results were primarily driven by recurring business earnings, with extraordinary items limited to an extraordinary loss of ¥0.02B. In the same period of the previous year, the Company recorded a one-time extraordinary gain of ¥5.1B from the sale of fixed assets, which was the primary cause of the decline in current-period Net Income. Non-operating income of ¥1.4B represented approximately 1.3% of revenue, indicating no excessive dependence, and consisted of stable sources such as interest and dividend income and equity-method income. The gap between Ordinary Income of ¥12.3B and Net Income of ¥9.0B (approximately a 27% decline) is consistent with the ¥3.3B tax burden. Excluding taxes, earnings quality can be assessed as having normalized after the reversal of the prior-year one-time factor. Nevertheless, the elevated levels of accounts receivable and inventories should be considered when assessing the quality of Operating Income from an accruals perspective.

Earnings Forecast and Guidance

Progress against the full-year forecast (Revenue of ¥408.0B, Operating Income of ¥28.0B, and Ordinary Income of ¥27.0B) was 27.1% for Revenue, 41.6% for Operating Income, and 45.7% for Ordinary Income in Q1, exceeding the standard quarterly progress rate of 25%. In particular, progress above the standard rate at the Operating Income and Ordinary Income levels reflects improved gross margins and a stable contribution from non-operating income and expenses. Progress toward Net Income (Company forecast: ¥45.0B) was somewhat slow at 20.1%, but this was a temporary impact caused by the reversal of the prior-year extraordinary gain and appears to have already been reflected in the full-year Company plan. The fact that the earnings forecast was revised during Q1 also indicates that management recognized changes from the initial plan for the fiscal year.

Shareholder Returns

The full-year dividend forecast is ¥240 per share, representing a full-year comparison with the prior-year dividend of ¥60 (data for the interim period or only part of the fiscal year). The Payout Ratio against the Company’s forecast EPS of ¥518.63 is approximately 46.3%, which can be assessed as a sustainable level given the Company’s financial soundness (Equity Ratio: 65.1%). No revision to the dividend forecast was made during the current quarter, and the dividend policy remains unchanged.

Risk Factors

1. Risk of prolonged working capital: Accounts receivable of ¥118.9B and inventories of ¥42.4B are high relative to the scale of revenue. If improvements in collection and inventory efficiency are delayed, this could affect the smoothing of Operating Cash Flow.

2. Risk of fluctuations in the value of investment securities: Investment securities increased substantially to ¥128.8B (15.0% of total assets), up +151.4% YoY, increasing the sensitivity of net assets (valuation difference) to market price fluctuations.

3. Risk of margin dilution due to changes in the business mix: The Functional Products Business (margin: 10.8%) is more profitable than the Chemicals Business (margin: 8.0%), and Functional Products revenue declined -2.2% YoY. Accordingly, changes in the business mix may affect the Company-wide margin.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Profitability is above the industry median, placing the Company relatively high within the manufacturing industry.

Growth and Capital Efficiency

The Revenue Growth Rate is below the industry median, indicating that top-line growth is relatively weak within the industry.

※Source: Compiled by the Company

Key Points from the Financial Results

1. The operating margin of 10.6% improved from the previous year, supported by an improved gross margin and control of SG&A expenses. The high margin of the Functional Products Business (10.8%) is driving Company-wide profitability, indicating a qualitative change in the business portfolio.

2. The -24.9% YoY decline in Net Income was caused by the reversal of the one-time ¥5.1B gain on the sale of fixed assets recorded in the previous year. Recurring earnings power excluding extraordinary items remained solid, as demonstrated by the +8.7% increase in Ordinary Income.

3. Investment securities increased substantially to ¥128.8B (+151.4% YoY), contributing to the increase in Comprehensive Income to ¥60.4B. At the same time, the resulting suppression of total asset turnover and contribution to the low ROE (1.6%) are noteworthy from a capital efficiency perspective.

Theoretical Share Price (Reference Value)

Sensitivity: ¥5,260–¥5,560 at ±1% for the Cost of Equity, and ¥5,374–¥5,428 at ±0.1 for ω.

Notes:

• Normalized EPS calculated from Ordinary Income and other figures is used to exclude the impact of temporary gains and losses (Company forecast EPS is ¥518.6).
• Because forecast ROE is below the Cost of Equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated using only publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL financial results summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed financial results data. Investment decisions should be made at your own responsibility, after consulting a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was operationally solid, with modest sales growth translating into stronger operating and ordinary profit, while reported net income declined because the prior-year quarter included a large asset-sale gain. Revenue increased 0.8% year on year to ¥11.04bn. Operating income rose 5.0% to ¥1.17bn, outperforming sales growth and evidencing positive operating leverage. Ordinary income increased 8.7% to ¥1.23bn, supported by a modestly improved non-operating balance. Gross profit increased 6.8% to ¥2.57bn despite limited top-line growth. Gross margin expanded by approximately 130bp year on year to 23.3% from 22.0%. Operating margin expanded by approximately 40bp to 10.6% from 10.1%. SG&A expense increased 8.4% to ¥1.40bn, faster than revenue growth, although gross-margin expansion more than offset this cost increase. Net income fell 24.9% to ¥0.90bn, and EPS was ¥104.13. The net-income decline is not indicative of a deterioration in the underlying operating business, as the prior-year quarter included a ¥0.51bn gain on sales of non-current assets. Excluding that prior-year gain, the current quarter's pre-tax profit of ¥1.23bn was above the prior-year underlying pre-tax level of roughly ¥1.04bn. The current quarter included only a ¥0.02bn extraordinary loss on disposal of fixed assets, leaving reported earnings substantially more recurring than the prior-year comparison base. Functional Products remained the core business by segment profit contribution, generating ¥0.62bn, or about 53% of total segment profit before eliminations. Comprehensive income rose sharply to ¥6.04bn, primarily reflecting a ¥5.26bn valuation gain on securities, which materially strengthened accumulated other comprehensive income but does not represent operating cash earnings. Liquidity ratios remain healthy, with a 166.6% current ratio and 144.0% quick ratio, while debt-to-equity is conservative at 0.54x. However, the working-capital cycle is elongated, with annualized DSO of 98 days, annualized DIO of 125 days, and an annualized cash conversion cycle of 175 days. The company also funds 71.4% of interest-bearing debt with short-term borrowings, creating a refinancing concentration despite adequate near-term liquidity. Full-year sales and operating-profit guidance implies Q1 progress rates of 27.0% and 41.6%, respectively, indicating that operating profit has started materially ahead of a standard 25% first-quarter run rate. Full-year net-income guidance implies only 20.1% Q1 progress, suggesting that management expects profit recognition to be weighted toward subsequent quarters, potentially including non-operating or non-recurring items.

Profitability Analysis

Annualized DuPont ROE is 6.5%, comprising an 8.2% net profit margin, 0.514x asset turnover, and 1.54x financial leverage. The principal structural constraint on return is asset turnover rather than leverage: the balance sheet is equity-rich and includes substantial fixed assets and investment securities. Financial leverage is moderate and does not suggest that the reported ROE is being artificially amplified by aggressive borrowing. The 10.6% EBIT margin is within the stated 'good' profitability range and improved by roughly 40bp year on year. Gross-margin expansion of approximately 130bp was the most important positive earnings driver, allowing operating income to grow 5.0% despite only 0.8% sales growth. The tax burden was 0.734, consistent with a normal effective tax rate of 26.5%. The interest burden was 1.056 because non-operating income exceeded interest expense; interest coverage of 22.84x indicates that financing cost is not currently a material drag on earnings. Chemical Products revenue increased 4.4% to ¥5.00bn, while segment profit increased 2.6% to ¥0.40bn; its segment margin was approximately 8.0%. Functional Products revenue declined 2.2% to ¥5.74bn, but segment profit rose 7.5% to ¥0.62bn, lifting segment margin to approximately 10.8% from 9.8%. This margin improvement in Functional Products is particularly important because it is the largest contributor to segment profit. Rental revenue was broadly stable at ¥0.24bn, while segment profit rose 9.4% to ¥0.15bn and its margin remained structurally high at approximately 62.8%. SG&A rose 8.4%, above revenue growth, and therefore requires monitoring; sustained profit expansion will depend on continued gross-margin resilience and Functional Products' margin recovery. The annualized ROE of 6.5% remains below the 8% benchmark despite strong Q1 operating margins, reflecting modest asset efficiency and a large equity base.

Growth Assessment

Revenue growth was limited to 0.8%, with stronger Chemical Products sales partly offset by a 2.2% decline in Functional Products sales. The earnings profile was nevertheless better than headline sales growth suggests because gross profit grew 6.8% and operating income grew 5.0%. Functional Products' ability to raise segment profit despite lower sales suggests improved product mix, pricing, or manufacturing efficiency, although the quarterly data do not isolate these factors. Chemical Products provided the principal top-line growth contribution but delivered lower incremental profit conversion than Functional Products. The rental business remains a small but high-margin stabilizer, contributing ¥0.15bn of segment profit from ¥0.24bn of sales. Q1 revenue reached 27.0% of the ¥40.80bn full-year forecast, slightly above the standard 25% first-quarter progress rate. Q1 operating income reached 41.6% of the ¥2.80bn full-year target, 16.6 percentage points above the standard progress rate. Q1 ordinary income reached 45.6% of the ¥2.70bn full-year target, also materially ahead of a normal seasonal run rate. In contrast, Q1 net income represented 20.1% of the ¥4.50bn full-year forecast, below the standard 25% pace. The disparity between operating-income and net-income progress indicates that the full-year net-income forecast likely assumes substantial later-period contributions outside the Q1 recurring earnings base. Revenue sustainability should be assessed against customer demand in Functional Products and Chemical Products, while the elevated inventory position raises the importance of confirming that production and stock levels convert into sales during subsequent quarters.

Financial Health

The balance sheet is financially sound on headline liquidity and leverage measures. Current assets of ¥31.28bn exceeded current liabilities of ¥18.77bn, resulting in working capital of ¥12.50bn and a current ratio of 166.6%. The quick ratio of 144.0% indicates that liquidity remains adequate even without relying on inventory liquidation. Total equity increased to ¥55.84bn from ¥50.32bn, and the equity ratio improved to 65.1% from 64.1%. Interest-bearing debt was ¥14.40bn, equivalent to 0.54x equity and 20.5% of total capital, both conservative solvency measures. Interest coverage of 22.84x provides a substantial cushion against current interest costs. The principal financial-structure concern is debt maturity concentration: short-term loans were ¥10.28bn, representing 71.4% of interest-bearing debt. Cash and deposits of ¥6.23bn covered 0.61x short-term debt, so the company relies on operating liquidity, receivable collection, and refinancing capacity rather than cash alone to address short-term maturities. This is not an immediate liquidity warning because the current and quick ratios exceed 1.0x, but it heightens sensitivity to credit-market conditions and working-capital release. Investment securities rose ¥7.76bn year on year to ¥12.89bn, a 151.4% increase, and represented 15.0% of total assets. The increase was accompanied by a ¥5.26bn valuation gain on securities in OCI and deferred tax liabilities of ¥4.98bn, making reported equity more sensitive to capital-market valuation movements. Accounts payable increased ¥1.19bn, or 36.8%, to ¥4.42bn, which provides some supplier financing support but does not offset the much longer receivable and inventory cycle. Net PPE was ¥33.97bn, equal to 39.6% of assets, confirming a capital-intensive manufacturing balance sheet. Construction in progress was ¥3.93bn, or approximately 11.6% of net PPE, indicating a meaningful investment pipeline that should be monitored for execution and return generation.

Notable B/S Changes

Investment securities: +¥7.76bn (+151.4%) to ¥12.89bn - the larger securities portfolio and ¥5.26bn valuation gain on securities materially increased OCI and equity sensitivity to market-price movements. Accounts payable: +¥1.19bn (+36.8%) to ¥4.42bn - supplier financing increased, partly supporting working capital, but it remains insufficient to neutralize elevated receivable and inventory days. Accumulated other comprehensive income: +¥5.14bn to ¥12.44bn - primarily reflects securities valuation gains and contributed to the increase in total equity to ¥55.84bn; this is market-sensitive rather than operating-profit-driven. Deferred tax liabilities: +¥2.62bn (+111.2%) to ¥4.98bn - consistent with unrealized valuation gains, particularly on investment securities, and reinforces the dependence of part of equity growth on OCI.

Cash Flow Quality

The reported earnings mix is more recurring in FY2027 Q1 than in the prior-year quarter. Current-quarter extraordinary loss was limited to ¥0.02bn, whereas the prior-year quarter included a ¥0.51bn gain on sales of non-current assets. Accordingly, the 24.9% decline in reported net income overstates the deterioration in underlying earnings. Working-capital quality is the principal area requiring attention. Annualized receivable days of 98 are above the 60-day warning threshold, indicating a long collection cycle for a manufacturing company. Annualized inventory days of 125 are also above the 90-day warning threshold, indicating substantial capital tied up in stock. The annualized cash conversion cycle of 175 days exceeds the 120-day warning threshold, combining slow collection and elevated inventory holding periods. This raises the risk that accounting profit may not translate promptly into operating cash generation if sales conversion or collections weaken. Finished goods were ¥4.24bn, raw materials were ¥3.86bn, and work in process was ¥3.47bn, demonstrating that inventory exposure extends across the production chain. Accounts payable of ¥4.42bn increased 36.8% year on year, which may partly support near-term cash conversion, but the extended receivable and inventory cycle remains the more material issue. The short-term-debt ratio of 71.4% compounds this working-capital risk because refinancing needs remain meaningful while cash is tied up in the operating cycle.

Dividend Sustainability

The full-year dividend forecast is ¥240 per share. Against forecast EPS of ¥518.63, the implied dividend payout ratio is approximately 46.3%. This is below the 60% sustainability benchmark and is moderate on an earnings basis. The payout level is also supported by a strong equity base of ¥55.84bn and conservative debt-to-equity of 0.54x. Dividend revision information indicates no change to the dividend forecast. The main factor to monitor is conversion of earnings into cash, given the long annualized 175-day cash conversion cycle and the concentration of debt in short-term borrowings. No share repurchase information is reported, so assessment is limited to the dividend payout ratio rather than total return ratio.

Risk Assessment

Business risks include Demand and product-mix risk in Functional Products: segment revenue declined 2.2% year on year despite a 7.5% rise in segment profit; sustaining margin gains with lower volumes may be difficult if customer demand remains soft., Chemical-industry input-cost and energy-price risk: the 130bp gross-margin improvement is positive, but specialty and inorganic chemical manufacturing remains exposed to raw-material, energy, and utility-cost volatility., Inventory realization risk: annualized DIO of 125 days is above the 90-day warning threshold; prolonged stockholding increases risks of slower turnover, pricing pressure, and inventory valuation pressure., Customer collection risk: annualized DSO of 98 days exceeds the 60-day warning threshold, making earnings and liquidity more exposed to collection timing and customer credit conditions., Securities-market risk: investment securities increased to ¥12.89bn and valuation gains on securities contributed ¥5.26bn to OCI; equity and comprehensive income are therefore exposed to market-price fluctuations., Capital-project execution risk: construction in progress of ¥3.93bn represents approximately 11.6% of net PPE, requiring timely completion and adequate utilization to earn acceptable returns..

Financial risks include Refinancing risk: short-term loans of ¥10.28bn account for 71.4% of total interest-bearing debt, substantially above the 40% quality-alert threshold. The maturity concentration raises dependence on bank refinancing and short-term funding market conditions, although current liquidity ratios remain healthy., Working-capital financing risk: annualized DSO of 98 days, annualized DIO of 125 days, and an annualized CCC of 175 days are all above warning thresholds. This creates a structural need to finance receivables and inventories for an extended period and could pressure liquidity if sales or collections weaken., Cash coverage of short-term debt is limited: cash and deposits of ¥6.23bn cover 0.61x of ¥10.28bn short-term loans. The company is not cash-funded for all near-term debt maturities, though working capital and credit metrics provide mitigating support., OCI volatility risk: the ¥5.26bn securities valuation gain materially lifted comprehensive income and equity, but this gain can reverse with equity-market movements and is not equivalent to operating profit..

Key concerns include Highest priority: the 175-day annualized cash conversion cycle, because it combines elevated receivable and inventory days and can impair cash conversion even when operating margins improve., High priority: the 71.4% short-term debt ratio, because refinancing requirements coincide with a working-capital-intensive operating model., Moderate priority: SG&A grew 8.4% versus revenue growth of 0.8%; further cost growth without sustained gross-margin improvement could reverse operating leverage., Moderate priority: full-year net-income guidance of ¥4.50bn materially exceeds full-year operating income guidance of ¥2.80bn, so the composition and recurrence of later-period non-operating or other gains will be important to evaluate., Moderate priority: FY2027 Q1 operating performance is stronger than the reported net-income comparison implies, but year-on-year comparability is distorted by the prior-year ¥0.51bn fixed-asset sale gain..

Investment Implications

Key takeaways include Operating momentum was positive: revenue rose 0.8%, operating income increased 5.0%, and operating margin improved to 10.6%., Functional Products is the core business by segment profit and delivered the strongest margin improvement, with segment profit up 7.5% despite a 2.2% sales decline., Reported net income fell 24.9%, but the decline primarily reflects the absence of the prior-year ¥0.51bn gain on sales of non-current assets rather than a deterioration in recurring operations., Balance-sheet leverage is conservative, with 0.54x debt-to-equity, 20.5% debt-to-capital, and 22.84x interest coverage., Liquidity is adequate, but working-capital efficiency and short-term debt concentration are the principal financial issues., The full-year operating-profit forecast appears conservatively paced after Q1, while the full-year net-income forecast appears dependent on stronger later-period profit contributions beyond Q1 recurring net income..

Metrics to watch include Functional Products revenue recovery and ability to sustain its approximately 10.8% segment margin, Chemical Products margin progression following Q1 sales growth, Annualized DSO of 98 days, annualized DIO of 125 days, and annualized CCC of 175 days, Short-term loans of ¥10.28bn and refinancing of the 71.4% short-term debt share, SG&A growth relative to revenue growth, Changes in investment securities and securities valuation gains/losses within OCI, Construction-in-progress conversion into productive fixed assets, Composition of profit required to achieve the ¥4.50bn full-year net-income forecast.

Regarding relative positioning, The company combines good operating margins, a strong equity base, and conservative leverage with sub-benchmark annualized ROE of 6.5%, reflecting modest asset turnover in a capital-intensive manufacturing model. Its balance-sheet resilience compares favorably with highly leveraged manufacturers, but its annualized 175-day cash conversion cycle and 71.4% short-term debt ratio are weaker than efficient manufacturing working-capital benchmarks.